Professor Simon Hart S.Hart@hull.ac.uk
Professor in Respiratory Medicine
SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)
People Involved
Project Acronym | SCENIC |
---|---|
Status | Project Complete |
Funder(s) | Hull University Teaching Hospitals NHS Trust |
Value | £17,918.00 |
Project Dates | May 1, 2019 - Jan 31, 2022 |
Partner Organisations | 00 No Partners |
You might also like
Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease Jun 30, 2017 - Aug 31, 2020
An in silico computational model of sarcoidosis
BREATHE: Breathlessness RElief AT HomE Apr 1, 2019 - Oct 31, 2021
A feasibility study to address this RQ:
Does a paramedic-administered short non-pharmacological complex breathlessness intervention improve breathlessness and reduce conveyance to ED for people with breathlessness crisis compared with usual pr...
Read More about BREATHE: Breathlessness RElief AT HomE.
Sir Jules Thorn PhD Scholarship Programme 2016 Sep 1, 2016 - Aug 31, 2019
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lungs that affects about 15,000 people in the UK. There is no curative treatment and 5-year survival in IPF is worse than many cancers. Despite this, the pathogenesis of IPF...
Read More about Sir Jules Thorn PhD Scholarship Programme 2016.
Characterisation of monocyte CD200R in pulmonary sarcoidosis Mar 1, 2016 - Feb 28, 2018
MABEL: A Parallel Group, Double-blind, Randomised Placebo-controlled Trial Comparing The Efficacy And Cost effectiveness Mar 1, 2019 - Feb 29, 2024
A parallel group, double-blind, randomised placebo-controlled trial comparing the efficacy and cost effectiveness of low dose oral modified release morphine (MRM) versus placebo on the intensity of breathlessness and daily activity in people with c...
Read More about MABEL: A Parallel Group, Double-blind, Randomised Placebo-controlled Trial Comparing The Efficacy And Cost effectiveness.